Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods.
Several studies suggest the importance of measuring the circulating concentrations of CNHs in the classification and/or prediction of mortality/ survival rates in patients with heart failure (1-4). In particular, a CNH assay might reduce the need for more expensive and invasive cardiac investigations in patients with cardiac disease (1-5). Because of the clinical relevance of CNH measurement, several different procedures have been proposed (3, 4). However, as yet the best procedure (gold standard) has not been ascertained, because CNH determination by competitive immunoassay methods is affected by several analytical problems (3, 4).
After we summarize the technical characteristics and potential clinical indications of various immunoassay methods for CNHs, their analytical performance and clinical relevance will be discussed and compared. Suggestions will be made for their use in clinical practice and for development of a new generation of CNH immunoassays.
MEASUREMENT OF ANP, BNP, AND RELATED PEPTIDES: WHICH PEPTIDE SHOULD BE MEASURED?
As reviewed recently (3, 4), developing a sensitive, precise, and accurate method for CNH assay has been difficult because of the structural, metabolic, and physiological characteristics of these hormones. Therefore, several important points should be taken into account when discussing the pathophysiological relevance of a particular CNH assay:
* The goal of a pathophysiological and/or clinical study should be to assess the activity of a specific hormone system; therefore, only the biologically active substances of this system should be assayed. As a consequence, only immunoassay methods using antibodies specific for the biologically active portion of the hormone (i.e., the part of the peptide chain recognized by the specific receptor) should be chosen to obtain a close relationship between biological and immunological activity (3, 4).
* Although ANP and BNP bind to the same specific receptors, they have different types of metabolism and spectra of biological activity, and their production and secretion may be regulated differently in humans (3, 4, 6, 7). It has been suggested that there may be different pools of intracellular natriuretic peptides that can respond separately to the same hemodynamic events (e.g., overload for ANP) or to the same pathology-related factors (e.g., cardiac hypertrophy for BNP) (7).
* ANP is stored in the atrial granules predominantly as [proANP.sub.1-126], which is split into a 98-amino acid N-terminal fragment (i.e., N-terminal [proANP.sub.1-98]), and ANP in equimolar amounts (1-4). Because N-terminal [proANP.sub.1-98], has a slower clearance than the biologically active peptide, its plasma concentration is higher (up to 10-50 times) than those of ANP and BNP (Table 1) (3, 4). Even if the N-terminal [proANP.sub.1-98], is biologically inactive, several studies (8-11) have indicated that some peptides, produced in vivo by the degradation of this peptide, are biologically active. These peptides have been named the long-acting natriuretic peptide (i.e., N-terminal [proANP.sub.1-30]); the vessel dilator peptide (i.e., [proANP.sub.31-67]); and the kaliuretic peptide (i.e., [proANP.sub.79-98]). However, these N-terminal proANP hormones exhibit (at least in part) different biological properties as well as different mechanisms of action (i.e., binding to different receptors) with respect to the ANP/BNP system (11, 12). Like ANP, BNP is also produced in the prohormone form ([proBNP.sub.1-108]), which before the secretion by cardiomyocytes is split into the inactive N-terminal fragment [proBNP.sub.1-76], and the biologically active hormone BNP (i.e., COOH-terminal [proANP.sub.77-108]) (3, 4, 12 ).
* CNHs are degraded both in vivo and in vitro by several proteases. EDTA and protease inhibitors (such as aprotinin) are generally added to whole blood samples to inhibit this degradation; plasma samples are then frozen and stored at -20[degrees]C as soon as possible (3, 4). This expensive and time-consuming procedure renders the use of the CNH assay in clinical routine practice difficult. However, recent studies have suggested that the use of protease inhibitors may be not necessary, at least for BNP and [proANP.sub.1-98], (13). If these findings are confirmed, the BNP and [proANP.sub.1-98], assays may be preferable to the ANP assay for routine clinical practice.
MEASUREMENT OF CNHS AND RELATED PEPTIDES BY IMMUNOASSAY METHODS
The determination of CNHs and related peptides is generally performed by means of competitive immunoassays, such as RIA or EIA; recently some noncompetitive immunoassays have been developed (3, 4). The analytical characteristics of immunoassays for ANP and BNP and those for N-terminal fragments of proANP and proBNP will be discussed separately in the following two sections because of their different analytical characteristics.
ANP AND BNP METHODS
There is no agreement on the best procedure for measuring ANP and BNP, because determination by competitive immunoassay methods is affected by several analytical problems. In particular, specific (i.e., metabolites or other peptides structurally related to CNHs) or nonspecific (such as plasma or cellular proteins binding CNHs) interferences may affect the assay (3, 4). Moreover, an assay detection limit of <1 pmol/L is required for the measurement of ANP and BNP concentrations in healthy subjects with acceptable precision (Table 1) (3, 4). For these reasons, preliminary extraction and/or chromatographic purification of large volumes (>1 mL) of plasma (or tissue extract) is required for eliminating these interferences, thus increasing accuracy (i.e., specificity) and sensitivity of the determination of competitive immunoassay methods (such as RIA or EIA) (4).
Noncompetitive immunometric assays for the measurement of ANP and BNP have been developed recently to overcome the problems encountered with competitive assays (3, 4). The methods of this second generation are generally "two-site" (sandwich) immunometric assays, using two specific monoclonal antibodies or antisera prepared against two sterically remote epitopes of the ANP (14-17) or BNP (18-20) peptide chain.
As reviewed recently (3, 4), noncompetitive immunoassay methods have several advantages over competitive assays. Noncompetitive assays are generally 5-20 times more precise and sensitive than their respective competitive assays and are not significantly affected by nonspecific or specific interference. Therefore, noncompetitive immunoassays methods for ANP and BNP do not usually require preliminary extraction and purification of the sample and also use a lower plasma volume (generally, 0.05-0.3 mL) than competitive assays (4). Furthermore, noncompetitive immunometric assays generally have a larger working range than that of competitive assays (4). These facts suggest that noncompetitive immunoassays for ANP and BNP may be more suitable for clinical routine than competitive assays (4).
ASSAYS FOR THE N-TERMINAL proANP AND proBNP
Theoretically, developing an immunoassay for N-terminal peptide fragments of proANP and proBNP should be easier than that for ANP and BNP, because these peptides have higher plasma concentrations (Table 1). However, immunoassays for N-terminal peptide fragments of proANP and pro BNP may also be affected by several analytical problems, mainly concerning the assay specificity.
The intact N-terminal [proANP.sub.1-98] is a long peptide; this implies that each anti-N-terminal proANP antibody recognizes only one epitope of the peptide. Consequently, because low-molecular mass fragments of N-terminal [proANP.sub.1-98] are present within the circulation, different competitive immunoassays, using different antibodies, may give different results (3, 4), as seen in Table 1.
EIA methods that use antisera specific for different epitopes of N-terminal [proANP.sub.1-98] peptide chain usually show cross-reactions close to 100% with the intact [proANP.sub.1-98] peptide (3, 4). Even if the values found with these EIAs are highly correlated when compared (r = 0.917; n = 115; P <0.0001), however, these methods show significantly different clinical results and reference values (Table 1).
These data agree closely with the results of other studies (21-23), indicating that RIAs for the assay, respectively, of the long-acting natriuretic peptide, the vessel dilator peptide, and the kaliuretic peptide actually also recognize the whole N-terminal [proANP.sub.1-98].
It is theoretically conceivable that a two-site noncompetitive immunometric assay, using two different monoclonal antibodies specific for two sterically remote epitopes of intact N-terminal [proANP.sub.1-98], would be more suitable than a competitive method to measure the intact N-terminal [proANP.sub.1-98], with only minor interference from its degradative fragments, as demonstrated recently for an IRMA method (24).
In conclusion, competitive and noncompetitive immunoassay methods for the N-terminal [proANP.sub.1-98] may measure, at least in part, different substances, which probably have different biological activities and metabolic pathways and thus different clinical relevance (8-11).
Noncompetitive assays for the determination of the N-terminal proBNP peptide, which use antisera or antibodies specific for different epitopes of the peptide chain, could also have different results, as demonstrated by the comparison of two EIA methods (Table 1). Recently, two noncompetitive immunoluminometric assays for N-terminal [BNP.sub.1-76], have also been described (25, 26). These immunoluminometric assay methods are highly sensitive (2-3 pmol/L) (25,26) and specific for the intact peptide chain N-terminal [BNP.sub.1-76], (25); furthermore, they could be easily modified for use in a fully automated system (25).
COMPARISON OF CLINICAL RELEVANCE OF IMMUNOASSAY METHODS FOR CNHS
Indications and usefulness of CNHs assays have been studied extensively for use in cardiovascular disease, especially in patients with various degrees of heart failure (1-4, 27-36). However, it must be emphasized that because CNHs are raised in a variety of clinical conditions (3,4), a normal value has only negative predictive value, whereas increased values usually call for further diagnostic investigation in patients with cardiovascular diseases (31,32).
Studies comparing the clinical usefulness of different CNH assays in patients with different degrees of heart failure have produced conflicting results. In some studies, the assay for N-terminal [proANP.sub.1-98] peptides was shown to be equally or even more clinically useful than other CNH assays (27-29), whereas in others (30,31,33-36) BNP was found to be the best marker of myocardial involvement.
Although these conflicting results could be partly explained by a heterogeneous nature of groups studied, the different specificities of methods used to measure the CNHs could also play an important role. Unfortunately, a comparison of analytical and clinical performances of these assays is difficult because the analytical characteristics of methods used are not always specified in clinical studies.
The ANP assay could be more useful than that of other CNHs in some pathophysiological conditions. ANP is produced predominantly in atrial cardiomyocytes and can be promptly released from these cells after an acute stimulation (atrial stretch and overload) (7). Furthermore, ANP has a shorter plasma half-life (~3-5 min) than BNP and especially intact N-terminal [proANP.sub.1-98] (3, 4). For these reasons, ANP should be a good marker of acute overload and/or rapid cardiovascular hemodynamic changes. Indeed, circulating concentrations of ANP decrease more after hemodialysis than those of BNP in patients with chronic renal failure (3, 4), whereas changes in plasma concentrations of intact N-terminal [proANP.sub.1-98] are less pronounced (Fig. 1). However, other causes should be also taken into account to explain the greater variations of ANP and BNP during hemodialysis compared with intact N-terminal [proANP.sub.1-98], such as the lower molecular weight of ANP and BNP than that of intact N-terminal [proANP.sub.1-98], allowing a better crossing through the hemodialysis membrane filter. Furthermore, ANP increases more than N-terminal [proANP.sub.1-98] during rapid ventricular pacing (37).
[FIGURE 1 OMITTED]
The assays of long-acting natriuretic peptide, vessel dilator peptide, and kaliuretic peptide, released simultaneously with ANP, should be also considered to be a marker of atrial stretch and overload.
Less information is available on the clinical relevance of the measurement of N-terminal [BNP.sub.1-76] compared with other CNH-related peptides (12,25,26); however, at present, this assay may have the same clinical indications as the intact N-terminal [proANP.sub.1-98], assay.
THE NEED FOR A NEW GENERATION OF IMMUNOASSAY METHODS
In Western countries, congestive heart failure is the most frequent hospital discharge for patients >65 years of age; in the United States alone, ~2.5 million patients suffer from heart failure (38). Several recent studies have underlined the clinical importance to routinely assay CNHs for classification, follow-up, and/or in prediction of mortality/ survival rates of all patients with heart failure (1-5,27-36).
This implies that reliable assays for CNHs must be available for all clinical laboratories; unfortunately, we are far from this goal. As reviewed previously in detail (4), developing a reliable assay for CNHs presents nearly insurmountable analytical problems. CNHs are a complex family of related peptides with both similar peptide chains and degradation pathways. Moreover, CNHs have greatly differing plasma concentrations (Table 1) and half-lives and may also undergo minor modifications in plasma, such as oxidation. For these reasons, several peptides may simultaneously interfere in an immunoassay, giving falsely high values. On the other hand, an assay that is very specific for a particular peptide may lead to underestimation, because peptide alteration may occur in the circulation, during specimen collection, or during storage.
Indeed, several methods for CNH assays have been described, but all have some problems concerning lack of sensitivity, precision, and/or accuracy (specificity). Furthermore, these methods, even when measuring similar or identical peptides, show different clinical results and reference values (Table 1) so that each laboratory has to determine its own reference interval.
CNHs and related peptides are generally measured with competitive immunoassay methods that use radioactive labels (i.e., RIA). The main advantage of RIAs compared with other immunoassays is the lower cost (4). The substitution of a RIA with a commercial noncompetitive immunoassay method may increase the cost for materials from two- to threefold (or more) in a laboratory, which has the opportunity to completely (or partially) set up an RIA without using expensive commercial products (i.e., the possibility of preparing specific antibodies and radioactive tracers directly) (4). However, radioactive tracers are less stable and safe than nonradioactive labels and can only be used in a few clinical laboratories.
Noncompetitive immunometric assays (such as some IRMAs) for CNHs generally have a better degree of sensitivity, precision, and specificity than the respective competitive immunoassays (such as RIA or EIA) (3,4). Therefore, this second generation of immunoassay methods should be preferred in all laboratories interested in pathophysiological and clinical research on CNHs, requiring a maximum sensitivity, precision, and accuracy. However, these methods are still time-consuming (an assay typically requires from 12 to 36 h) and cannot be used in a fully automated analytical system.
Because at present there is no a general consensus on the best method for CNH assay, at the present time each laboratory must choose the methods and the peptides (hormones) to assay that meet its own clinical requirements as well as to other issues, such as stability (of both analytes and materials), ease of measurement, and costs.
In our opinion, to allow a more widespread propagation of CNH assay in all clinical laboratories and routine clinical practice it is necessary to set up a new generation of noncompetitive immunometric assays that are more sensitive, precise, and easy to perform, do not use radioactive labels, and can be directly used in fully automated analytical systems. Indeed, some recently developed immunoluminometric assay methods for N-terminal [proBNP.sub.1-76] show some of above-cited analytical characteristics (including their possible use in a fully automated system); therefore, they should be taken as a starting point for the development of a new generation of CNH immunoassays (25, 26). More recently, a rapid, fully automated method for BNP assay, which could be used for point-of-care testing of patients with congestive heart failure, has also been described (39).
Three main problems must be resolved to allow widespread propagation of CNH assay in clinical practice, including their use in emergency and primary care, as suggested by several authors (1-4, 31):
(a) An increase in analytical sensitivity should be achieved. This improvement should allow the determination of all the normal range of CNHs with an acceptable CV (<15%); this goal is particularly pressing for the BNP assay (4,19, 20). As demonstrated recently for other hormone immunoassays (for example, for thyroid-stimulating hormone assay), an increase in the analytical sensitivity also produces an increase in functional (clinical) sensitivity (40).
(b) An increase in analytical specificity (accuracy) is also necessary, in particular for the assay of [proANP.sub.1-98]-and [proBNP.sub.1-76]-related peptides and hormones.
(c) An increase in practicability is also necessary. We think that it will not be possible to spread the routine measurement of CNHs in clinical practice, including in emergency and primary care, without a new generation of immunoassay methods that permit the determination of CNHs in a few hours (or even minutes).
(1.) Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease [Review]. Am Heart J 1998;135:914-23.
(2.) Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases [Review]. Clin Sci 1998;95:519-29.
(3.) Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans [Review]. Horm Metab Res 1999;31:487-98.
(4.) Clerico A, Iervasi G, Del Ry S, Giannessi D. Immunoassay methods for the measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in humans. J Clin Ligand Assay 1999;22:194-204.
(5.) Struthers AD. Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? [Editorial]. Br Heart J 1993;70:397-8.
(6.) Yoshibayashi M, Saito Y, Nakao K. Brain natriuretic peptide versus atrial natriuretic peptide--physiological and pathophysiological significance in children and adults: a review. Eur J Endocrinol 1996;135:265-8.
(7.) De Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart [Review]. Cardiovasc Res 1996;31:7-18.
(8.) Gower WR Jr, Chiou S, Skolnick KA, Vesely DL. Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 1994;15:861-7.
(9.) Vesely DL, Douglass MA, Dietz JR, Gower WR, McCormick MT, Rodriguez-Paz G, Schocken DD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-40.
(10.) Overton RM, Vesely DL. Processing of kaliuretic peptide in human plasma and serum. Peptides 1996;17:1041-6.
(11.) Overton RM, Vesely DL. Processing of long-acting natriuretic peptide and vessel dilator in human plasma and serum. Peptides 1996;17:1155-6.
(12.) Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-96.
(13.) Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999;97:689-95.
(14.) Lewis HM, Ratcliffe WA, Stott RAW, Wilkins MR, Baylis PH. Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma. Clin Chem 1989;35:953-7.
(15.) Tattersal JE, Dawnay A, McLean C, Cattel WR. Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma. Clin Chem 1990;36:855-9.
(16.) Tsuji T, Masuda H, Imagawa K, Haraikawa M, Shibata K, Kono M, et al. Stability of human atrial natriuretic peptide in blood samples. Clin Chim Acta 1994;225:171-7.
(17.) Clerico A, Iervasi G, Del Chicca MG, Maffei S, Berti S, Sabatino L, et al. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure. Clin Chem 1996;42:1627-33.
(18.) Kono M, Yamauchi A, Tsuji T, Misaka A, Igano K, Ueki K, et al. An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaku 1993;13:2-7.
(19.) Clerico A, lervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-8.
(20.) Del Ry S, Clerico A, Giannessi D, Andreassi MG, Caprioli R, Iascone MR, et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an IRMA method. Scand J Clin Lab Invest 2000;60:81-90.
(21.) Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus, a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
(22.) Buckley MG, Markandu ND, Sagnella GA, MacGregor GA. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). Clin Sci 1994;87:311-7.
(23.) Macauly Hunter EF, Kelly PA, Prowse C, Woods RJ, Lowry PJ. Analysis of peptides derived from pro-atrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest 1998;58:205-16.
(24.) Numata Y, Dohl K, Furukawa A, Kikuka S, Asada H, Fukunaga T, Taniguchi Y, Sasakura K, Tsuji T, Inouye K, Yoshimura M, Itoh H, Mukoyama M, Nakao K. Immunoradiometric assay for N-terminal fragment of proatrial natriuretic peptide (N-terminal proANP) in human plasma. Clin Chem 1998;44:1008-13.
(25.) Hughes D, Talwar S, Squire IB, Davies JE, Ng LL. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 1999;96:373-80.
(26.) Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J. Development of a novel, N-terminal-proBNP (NTproBNP) assay with a low detection limit. Scand J Clin Lab Invest 1999;59(Suppl 230):177-81.
(27.) Davidson NC, Naas AA, Hanson JK, Kennedy NSJ, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and n-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
(28.) Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997;36:246-55.
(29.) Muders F, Kromer EP, Griese DP, Pfeifer M, Henser HW, Riegger GAJ, et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997;134:442-9.
(30.) Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-7.
(31.) Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51.
(32.) Cheung BM, Kumana CR. Natriuretic peptides-relevance in cardiovascular disease. JAMA 1998;280:1983-4.
(33.) McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
(34.) Kling R, Hystad M, Kjekshus J, Karlberg BE, Djoseland O, Aakvaag A, Hall C. An experimental study of cardiac natriuretic peptides as marker of development of congestive heart failure. Scand J Clin Lab Invest 1998;58:683-91.
(35.) Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999;81:114-20.
(36.) Uusimaa P, Ruskoaho H, Vuolteenabo O, Niemela M, Lumme J, Ikaheimo M, Jounela A, Peuhkurinen K. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 1999;69:5-14.
(37.) Ylitalo K, Uusimaa P, Vuolteenaho O, Ruskoaho H, Peuhkurinen K. Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing. Pacing Clin Electrophysiol 1999;22:1064-70.
(38.) McLaughlin MA, Cassel CK. Demography and epidemiology of cardiovascular disease in old age. In: Chesler E, ed. Clinical cardiology in the elderly, 2nd ed. Armonk, NY: Futura Publishing Company, Inc., 1999:3-16.
(39.) Wieczorek SJ, Bailly KR, Thomas P, Wu AHB, Hager D, Ferrier A, et al. Clinical evaluation of the triage B-type natriuretic peptide assay for point of care testing of patients with congestive heart failure [Abstract]. Clin Chem 2000;46:A77.
(40.) Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays [Review]. Clin Chem 1996;42:140-5.
ALDO CLERICO,* SILVIA DEL RY, and DANIELA GIANNESSI
Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, University of Pisa, 56100 Pisa, Italy.
* Address correspondence to this author at: Laboratory of Cardiovascular Endocrinology, Cell Biology, and Molecular Genetics, Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology, via Savi S, 56100 Pisa, Italy. Fax 39-050-553461; e-mail email@example.com.
Received February 17, 2000; accepted July 13, 2000.
 Nonstandard abbreviations: CNFL cardiac natriuretic hormone; ANP, atrial natriuretic peptide; and BNP, brain natriuretic peptide.
Table 1. Mean detection limit, normal values (mean [+ or -] SD), and range (minimum and maximum values) of some competitive (EIA) and noncompetitive (IRMA and ELISA) immunoassays for CNHs. Detection Normal values, Range, Method (a) limit, pmol/L pmol/L pmol/L IRMA ANP 0.73 5.6 [+ or -] 3.6 0.2-16.6 IRMA BNP 0.75 2.9 [+ or -] 2.7 0.1-12.4 ELISA [proANP.sub.1-98] 76.9 731 [+ or -] 628 43-1502 IRMA [proANP.sub.1-98] 40.5 228 [+ or -] 99 63-422 EIA [proANP.sub.1-30] 9.5 708 [+ or -] 251 44-1289 EIA [proANP.sub.31-67] 38.4 1422 [+ or -] 790 193-3339 EIA Nt-proBNP 13.6 246.8 [+ or -] 120.1 64-488 EIA Mid-proBNP 4.0 117.5 [+ or -] 100.3 0.2-368 (a) ANP was measured by a previously described IRMA method (17, 19). BNP was measured by a previously described IRMA method (19, 20). The following methods were from Biomedica Gruppe (Vienna, Austria): ELISA [proANP.sub.1-98] method (code BI-20892); EIA [proANP.sub.1-30] method (code BI-20802); EIA [proANP.sub.31-67] method (code BI-20822); EIA Nt-pro BNP method (code BI-20852), which uses an antiserum against the N-terminal [proBNP.sub.8-29] peptide fragment; and EIA Mid-proBNP method (code BI-20862), which uses an antiserum against the N-terminal [proBNP.sub.32-57] peptide fragment. IRMA [proANP.sub.1-98] was kindly supplied by Shionogi and Co., Ltd. (Osaka Japan), described previously (24).
|Printer friendly Cite/link Email Feedback|
|Author:||Clerico, Aldo; Del Ry, Silvia; Giannessi, Daniela|
|Date:||Oct 1, 2000|
|Previous Article:||Detection of prevalent genetic alterations predisposing to hemochromatosis and other common human diseases.|
|Next Article:||Transferrin polymorphism influences iron status in blacks.|